Reviva Pharmaceuticals, Inc., (Reviva) headquartered in San Jose, California, is a fast growing privately held, late-stage clinical development pharmaceutical company. Reviva is developing a portfolio of internally discovered next generation innovative therapies using chemical genomic driven approaches and proprietary technologies that addresses unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic and inflammatory diseases. Reviva has multiple products in the pipeline at various stages of development and they are for chronic conditions in large therapeutic areas. Reviva has a strong patent portfolio with over 90 filed patents and 30 granted patents. The company’s flagship product RP5063, a novel antipsychotic drug is projected to reach market in early 2017.
Reviva leadership and management team comprised of highly successful and experienced professionals in the pharmaceutical industry and some of them contributed to blockbuster category drugs currently in the global market.